Processes to manage analyses and publications in a phase III multicenter randomized clinical trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Snow, Kristin K ^a,b   Bell, Margaret C ^a   Stoddard, Anne M ^a   Curto, Teresa M ^a   Wright, Elizabeth C ^c   Dienstag, Jules L ^d,e  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b NEW HAMPSHIRE DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Authorship allocation; Authorship assignment; HALT C trial; Publication guidelines; Publication management; Publication processes

Indexed keywords

ARTICLE; DATA ANALYSIS; HUMAN; MEDICAL LITERATURE; MULTICENTER STUDY (TOPIC); PEER REVIEW; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; WRITING; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; HEPATITIS C; INFORMATION DISSEMINATION; METHODOLOGY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL; STANDARDS; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ANTIVIRAL AGENTS; CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HEPATITIS C; HUMANS; INFORMATION DISSEMINATION; INTERFERON-ALPHA; MANUSCRIPTS, MEDICAL; PEER REVIEW, RESEARCH; PERIODICALS AS TOPIC; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RESEARCH DESIGN; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84901951546     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-159     Document Type: Article

References (83)

1. Dowsett SA, Van Campen LE, Bednar LA. Developing good scientific publishing practices: one pharmaceutical company's perspective. Curr Med Res Opin 2010, 26:1249-1254. 10.1185/03007991003748880, 20350148.
2. Larson EL, Cortazal M. Publication guidelines need widespread adoption. J Clin Epidemiol 2012, 65:239-246. 10.1016/j.jclinepi.2011.07.008, 22000815.
3. Parker RA, Berman NG. Criteria for authorship for statisticians in medical papers. Stat Med 1998, 17:2289-2299. 10.1002/(SICI)1097-0258(19981030)17:20<2289::AID-SIM931>3.0.CO;2-L, 9819828.
4. Dulhunty JM, Boots RJ, Paratz JD, Lipman J. Determining authorship in multicenter trials: a systematic review. Acta Anaesthesiol Scand 2011, 55:1037-1043. 10.1111/j.1399-6576.2011.02477.x, 21689076.
5. Bialy S, Blessing JA, Stehman FB, Reardon AM, Blaser KM. Gynecologic oncology group strategies to improve timeliness of publication. Clin Trials 2013, 10:617-623. 10.1177/1740774513490249, 23794406.
6. Hopewell S, Clarke M, Stewart L, Tierney J. Time to publication for results of clinical trials. Cochrane Database Syst Rev 2007, 2:MR000011.
7. Ross JS, Mocanu M, Lampropulos JF, Tse T, Krumholz HM. Time to publication among completed clinical trials. JAMA Intern Med 2013, 173:825-828. 10.1001/jamainternmed.2013.136, 3691813, 23460252.
8. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ 2012, 344:d7292. 10.1136/bmj.d7292, 3623605, 22214755.
9. Smith E, Williams-Jones B. Authorship and responsibility in health sciences research: a review of procedures for fairly allocating authorship in multi-author studies. Sci Eng Ethics 2012, 18:199-212. 10.1007/s11948-011-9263-5, 21312000.
10. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE, and the HALT-C Trial Group Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004, 25:472-492. 10.1016/j.cct.2004.08.003, 15465617, and the HALT-C Trial Group.
11. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, for the HALT-C Trial Investigators Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359:2429-2441. 10.1056/NEJMoa0707615, 2606037, 19052125, for the HALT-C Trial Investigators.
12. Uniform requirements for manuscripts submitted to biomedical journals International committee of medical journal editors. N Engl J Med 1991, 324:424-428. Uniform requirements for manuscripts submitted to biomedical journals.
13. Bell MC, Robuck PR, Wright EC, Mihova MS, Hofmann C, De Santo JL, Milstein SL, Richtmyer PA, Shelton JL, Cormier M, King DL, Park CJ, Molchen WA, Park Y, Kelley M. Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Trials 2009, 6:618-627. 10.1177/1740774509348525, 3753781, 19889888.
14. Bieliauskas LA, Back-Madruga C, Lindsay KL, Snow KK, Kronfol Z, Lok AS, Padmanabhan L, Fontana RJ. Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis. J Clin Exp Neuropsychol 2006, 28:1346-1361. 10.1080/13803390500473720, 17050262.
15. Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok AS, Fontana RJ. Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. J Int Neuropsychol Soc 2007, 13:687-692.
16. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C, and the HALT-C Trial Group Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006, 131:1440-1451. 10.1053/j.gastro.2006.08.036, 17101320, and the HALT-C Trial Group.
17. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, and the HALT-C Trial Group Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007, 46:420-431. 10.1016/j.jhep.2006.10.009, 1995129, 17196293, and the HALT-C Trial Group.
18. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR, and the HALT-C Trial Group Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005, 43:434-441. 10.1016/j.jhep.2005.03.019, 16136646, and the HALT-C Trial Group.
19. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, and the HALT-C Trial Group Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006, 44:1675-1684. 10.1002/hep.21440, 17133499, and the HALT-C Trial Group.
20. Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther 2007, 26:401-410. 10.1111/j.1365-2036.2007.03389.x, 17635375.
21. Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Desanto JL, Curto TM, Wright EC. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther 2009, 29:589-601. 10.1111/j.1365-2036.2008.03908.x, 3767280, 19053983.
22. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kulig CC, Curto TM, Wright EC. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C anti-viral long-term treatment against cirrhosis trial. Aliment Pharmacol Ther 2008, 27:798-809. 10.1111/j.1365-2036.2008.03639.x, 18266997.
23. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok AS, Padmanabhan L. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 2005, 43:614-622. 10.1016/j.jhep.2005.04.006, 16237784.
24. Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok AS, Kronfol Z, Padmanabhan L. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 2007, 45:1154-1163. 10.1002/hep.21633, 17465000.
25. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008, 47:789-798. 10.1002/hep.22099, 18175357.
26. Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C, Lok AS, Stoddard AM. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol 2008, 103:2766-2775. 10.1111/j.1572-0241.2008.02106.x, 3712502, 18721241.
27. Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR, and the HALT-C Trial Group Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol 2006, 101:983-992. 10.1111/j.1572-0241.2006.00461.x, 16573786, and the HALT-C Trial Group.
28. Lindsay K, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok ASF, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG, for the HALT-C Trial Group Blunted cytopenias and weight loss: new correlates of virologic null response to retreatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008, 6:234-241. 10.1016/j.cgh.2007.11.020, 18237873, for the HALT-C Trial Group.
29. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C, and the HALT-C Trial Group Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol 2007, 5:245-254. 10.1016/j.cgh.2006.11.002, 17296533, and the HALT-C Trial Group.
30. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005, 42:282-292.
31. Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O'Brien TR. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008, 49:548-556. 10.1016/j.jhep.2008.05.011, 3903339, 18619701.
32. Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol 2004, 42:421-425. 10.1128/JCM.42.1.421-425.2004, 321650, 14715796.
33. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM, and the HALT-C Trial Group Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008, 48:1412-1419. 10.1002/hep.22487, 2804270, 18816437, and the HALT-C Trial Group.
34. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR, and the HALT-C Trial Group HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006, 44:360-367. 10.1002/hep.21265, 16871570, and the HALT-C Trial Group.
35. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL, and the HALT-C Trial Group Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis 2006, 193:931-940. 10.1086/500952, 16518754, and the HALT-C Trial Group.
36. Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 2010, 51:137-148. 3746312, 20332289.
37. Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR. Comparison of amplification enzymes for hepatitis C virus quasispecies analysis. Virol J 2005, 2:41. 10.1186/1743-422X-2-41, 1090623, 15847697.
38. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ, and the HALT-C Trial Group Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 2005, 41:617-625. 10.1002/hep.20581, 15726656, and the HALT-C Trial Group.
39. Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, and the HALT-C Trial Group The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 2006, 64:855-864. 10.1016/j.gie.2006.03.007, 17140886, and the HALT-C Trial Group.
40. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG, and the HALT-C Trial Group Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) Trial. Hepatology 2008, 47:605-612. and the HALT-C Trial Group.
41. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE, and the HALT-C Trial Group Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126:1015-1023. discussion 1947, 10.1053/j.gastro.2004.01.014, 15057741, and the HALT-C Trial Group.
42. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103-112. 10.1053/j.gastro.2006.11.011, 17241864.
43. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR, and the HALT-C Trial Group Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009, 49:1847-1858. 10.1002/hep.22877, 2692559, 19434718, and the HALT-C Trial Group.
44. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009, 137:549-557. 10.1053/j.gastro.2009.05.007, 3148692, 19445938.
45. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011, 140:1961-1969. 10.1053/j.gastro.2011.02.061, 3109110, 21376050.
46. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C, and the HALT-C Trial Group Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2009, 49:1828-1837. 10.1002/hep.22865, 2692566, 19291787, and the HALT-C Trial Group.
47. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ, and the HALT-C Trial Group Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009, 51:585-594. and the HALT-C Trial Group.
48. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Litman HJ, Lok AS, Kronfol Z. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 2010, 105:1551-1560. 10.1038/ajg.2010.3, 3772520, 20104219.
49. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010, 59:1401-1409. 10.1136/gut.2010.207423, 3740000, 20675691.
50. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE, and the HALT-C Trial Group Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010, 138:2321-2331. 10.1053/j.gastro.2010.02.058, 2883673, 20211180, and the HALT-C Trial Group.
51. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL, and the HALT-C Trial Group Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010, 138:136-146. 10.1053/j.gastro.2009.09.007, 2813393, 19766643, and the HALT-C Trial Group.
52. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C, and the HALT-C Trial Group Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009, 50:1738-1749. 10.1002/hep.23211, 3707633, 19824074, and the HALT-C Trial Group.
53. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010, 138:493-502. 10.1053/j.gastro.2009.10.031, 2819612, 19852963.
54. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010, 8:877-883. 10.1016/j.cgh.2010.03.025, 3771318, 20362695.
55. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG, and the HALT-C Trial Group Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009, 137:1986-1994. 10.1053/j.gastro.2009.08.067, 3774149, 19747918, and the HALT-C Trial Group.
56. Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Morgan TR, Dienstag JL, Ghany MG, AMDIB Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010, 31:719-734. 10.1111/j.1365-2036.2010.04235.x, 2923484, 20070284, AMDIB.
57. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE, and the HALT-C Trial Group A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011, 54:396-405. 3144992, 21520194, and the HALT-C Trial Group.
58. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, Sinha R, Everhart JE. Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against Cirrhosis trial. Aliment Pharmacol Ther 2010, 33:127-137. 3490214, 21083592.
59. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL, Group H-CT Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011, 140:1490-1500. e1493, 10.1053/j.gastro.2011.01.053, 3081953, 21335007, Group H-CT.
60. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, and the HALT-C Trial Group Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010, 52:833-844. 10.1002/hep.23744, 2932862, 20564351, and the HALT-C Trial Group.
61. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat 2012, 19:404-413. 10.1111/j.1365-2893.2011.01562.x, 3349971, 22571902.
62. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in hepatic inflammation is associated with less fibrosis progression and fewer clinical outcomes in advanced hepatitis C. Am J Gastroenterol 2012, doi:10.1038/ajg.2012.137.
63. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One 2011, 6:e20904. 10.1371/journal.pone.0020904, 3132753, 21760886.
64. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C trial cohort. Dig Dis Sci 2011, 56:564-568. 10.1007/s10620-010-1507-8, 3142358, 21136163.
65. Kronfol Z, Litman HJ, Back-Madruga C, Bieliauskas LA, Lindsay KL, Lok AS, Fontana RJ, Group H-CT. No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord 2011, 129:205-212. 10.1016/j.jad.2010.09.010, 3025085, 20889211.
66. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT, Group H-CT. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One 2012, 7:e27144. 10.1371/journal.pone.0027144, 3281016, 22359532.
67. Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ. Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics 2011, 21:851-860. 10.1097/FPC.0b013e32834c3e74, 3215092, 21946897.
68. Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D, Group H-CTS Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol 2011, 106:884-893. 10.1038/ajg.2010.456, 3772514, 21139575, Group H-CTS.
69. Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C trial. Gastroenterology 2011, 141:900-908. e901-902, 10.1053/j.gastro.2011.06.007, 3773843, 21699796.
70. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, and the HALT-C Trial Group Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011, 140:840-849. e841, 10.1053/j.gastro.2010.11.050, 3057272, 21129375, and the HALT-C Trial Group.
71. O'Bryan JM, Potts JA, Bonkovsky HL, Mathew A, Rothman AL. Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes. PLoS One 2011, 6:e20922. 10.1371/journal.pone.0020922, 3150344, 21829595.
72. Rakoski MO, Brown MB, Fontana RJ, Bonkovsky HL, Brunt EM, Goodman ZD, Lok AS, Omary MB. Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011, 9:902-909. e901, 10.1016/j.cgh.2011.07.006, 3400531, 21782771.
73. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR, Group H-CT. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011, 54:434-442. 10.1002/hep.24257, 3134544, 21374690.
74. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012, 107:64-74. 10.1038/ajg.2011.312, 3903319, 21931376.
75. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT, Group H-CT. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011, 141:141-149. 10.1053/j.gastro.2011.03.045, 3129453, 21440548.
76. Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int 2012, 32:665-674. 10.1111/j.1478-3231.2011.02686.x, 3299849, 22103814.
77. Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS, Group H-CT. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology 2011, 54:1527-1537. 10.1002/hep.24550, 3718548, 22045670.
78. Bonkovsky HL, Lambrecht RW, Naishadham D. Genetic variations in heme oxygenase-1 and chronic hepatitis. Hepatology 2010, 52:400-401. 10.1002/hep.23562, 20232486.
79. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Obstet Gynecol 2009, 114:1341-1345. 10.1097/AOG.0b013e3181c3020d, 19935040.
80. Scherer RW, Langenberg P, Von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev 2007, 2:MR000005.
81. Turner S, Wright D, Maeso R, Cook A, Milne R. Publication rate for funded studies from a major UK health research funder: a cohort study. BMJ Open 2013, 3:e002521. 3646183, 23645914.
82. National Institute of Diabetes and Digestive and Kidney Diseases Central Repository. [https://www.niddkrepository.org/].
83. Almasio PL. HALT-C in the final analysis: a molehill out of a mountain. J Hepatol 2009, 50:1280-1282. 10.1016/j.jhep.2009.03.001, 19398229.